相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nucleotide-binding mechanisms in pseudokinases
Henrik M. Hammaren et al.
BIOSCIENCE REPORTS (2016)
Cysteinome: The first comprehensive database for proteins with targetable cysteine and their covalent inhibitors
Sijin Wu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix
Emilie Leroy et al.
BIOCHEMICAL JOURNAL (2016)
The evolving world of pseudoenzymes: proteins, prejudice and zombies
Patrick A. Eyers et al.
BMC BIOLOGY (2016)
(WNK)ing at death: With-no-lysine (Wnk) kinases in neuropathies and neuronal survival
Bor Luen Tang
BRAIN RESEARCH BULLETIN (2016)
Targeting biomolecules with reversible covalent chemistry
Anupam Bandyopadhyay et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2016)
Stapled peptides: providing the best of both worlds in drug development
Xiayang Xie et al.
FUTURE MEDICINAL CHEMISTRY (2016)
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
Srdan Verstovsek et al.
HAEMATOLOGICA (2016)
The Pseudokinase MLKL and the Kinase RIPK3 Have Distinct Roles in Autoimmune Disease Caused by Loss of Death-Receptor-Induced Apoptosis
Silvia Alvarez-Diaz et al.
IMMUNITY (2016)
Development of Specific, Irreversible Inhibitors for a Receptor Tyrosine Kinase EphB3
Alvin Kung et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2016)
KinView: a visual comparative sequence analysis tool for integrated kinome research
Daniel Ian McSkimming et al.
MOLECULAR BIOSYSTEMS (2016)
Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling
Neil S. Dhawan et al.
NATURE (2016)
Overcoming resistance to HER2 inhibitors through state-specific kinase binding
Chris J. Novotny et al.
NATURE CHEMICAL BIOLOGY (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
ATP-Competitive MLKL Binders Have No Functional Impact on Necroptosis
Bin Ma et al.
PLOS ONE (2016)
Structural Basis for the Non-catalytic Functions of Protein Kinases
Jennifer E. Kung et al.
STRUCTURE (2016)
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
Srdan Verstovsek et al.
HAEMATOLOGICA (2016)
Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase
Joerg O. Schulze et al.
CELL CHEMICAL BIOLOGY (2016)
The Tribbles 2 (TRB2) pseudokinase binds to ATP and autophosphorylates in a metal-independent manner
Fiona P. Bailey et al.
BIOCHEMICAL JOURNAL (2015)
Going for broke: targeting the human cancer pseudokinome
Fiona P. Bailey et al.
BIOCHEMICAL JOURNAL (2015)
Tribbles pseudokinases: novel targets for chemical biology and drug discovery?
Daniel M. Foulkes et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2015)
The role of TRIB1 in lipid metabolism; from genetics to pathways
Sadahiko Iwamoto et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2015)
Tribbles in inflammation
Jessica Johnston et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2015)
Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)
Xiaoshan Min et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain
John S. Tokarski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Mitochondrial ADCK3 Employs an Atypical Protein Kinase-like Fold to Enable Coenzyme Q Biosynthesis
Jonathan A. Stefely et al.
MOLECULAR CELL (2015)
ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation
Henrik M. Hammaren et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Molecular Mechanism of CCAAT-Enhancer Binding Protein Recruitment by the TRIB1 Pseudokinase
James M. Murphy et al.
STRUCTURE (2015)
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
Margit Hagel et al.
CANCER DISCOVERY (2015)
Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
Eric R. Goedken et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Isoform-Selective Disruption of AKAP-Localized PKA Using Hydrocarbon Stapled Peptides
Yuxiao Wang et al.
ACS CHEMICAL BIOLOGY (2014)
The molecular regulation of Janus kinase (JAK) activation
Jeffrey J. Babon et al.
BIOCHEMICAL JOURNAL (2014)
Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses
Leila N. Varghese et al.
BIOCHEMICAL JOURNAL (2014)
Insights into the evolution of divergent nucleotide-binding mechanisms among pseudokinases revealed by crystal structures of human and mouse MLKL
James M. Murphy et al.
BIOCHEMICAL JOURNAL (2014)
A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties
James M. Murphy et al.
BIOCHEMICAL JOURNAL (2014)
Drug discovery considerations in the development of covalent inhibitors
Robert Mah et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
Drugging MYCN through an Allosteric Transition in Aurora Kinase A
William Clay Gustafson et al.
CANCER CELL (2014)
被撤回的出版物: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase (Retracted article. See vol. 24, pg. 917, 2017)
Peter Littlefield et al.
CHEMISTRY & BIOLOGY (2014)
Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases
Sandra W. Cowan-Jacob et al.
FUTURE MEDICINAL CHEMISTRY (2014)
MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance
Richard Ottman et al.
MOLECULAR CANCER (2014)
WNK1-OSR1 kinase-mediated phospho-activation of Na+-K+-2Cl- cotransporter facilitates glioma migration
Wen Zhu et al.
MOLECULAR CANCER (2014)
Dimeric Structure of Pseudokinase RNase L Bound to 2-5A Reveals a Basis for Interferon-Induced Antiviral Activity
Hao Huang et al.
MOLECULAR CELL (2014)
Mass-spectrometry-based draft of the human proteome
Mathias Wilhelm et al.
NATURE (2014)
Pharmacological targeting of the pseudokinase Her3
Ting Xie et al.
NATURE CHEMICAL BIOLOGY (2014)
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
Bryan R. Lannine et al.
NATURE CHEMICAL BIOLOGY (2014)
Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death
Joanne M. Hildebrand et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Structure of Human RNase L Reveals the Basis for Regulated RNA Decay in the IFN Response
Yuchen Han et al.
SCIENCE (2014)
Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations
Peter Littlefield et al.
SCIENCE SIGNALING (2014)
Chloride Sensing by WNK1 Involves Inhibition of Autophosphorylation
Alexander T. Piala et al.
SCIENCE SIGNALING (2014)
A Plug Release Mechanism for Membrane Permeation by MLKL
Lijing Su et al.
STRUCTURE (2014)
Day of the dead: pseudokinases and pseudophosphatases in physiology and disease
Veronika Reiterer et al.
TRENDS IN CELL BIOLOGY (2014)
Titin kinase is an inactive pseudokinase scaffold that supports MuRF1 recruitment to the sarcomeric M-line
Julijus Bogomolovas et al.
OPEN BIOLOGY (2014)
Development of an ALK2-Biased BMP Type I Receptor Kinase Inhibitor
Agustin H. Mohedas et al.
ACS CHEMICAL BIOLOGY (2013)
The functionally diverse roles of tribbles
Fiona Lohan et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2013)
The dual function of KSR1: a pseudokinase and beyond
Hua Zhang et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2013)
Pseudokinase drug intervention: a potentially poisoned chalice
Jeroen Claus et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2013)
Pseudokinases from a structural perspective
Susan S. Taylor et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2013)
Dawn of the dead: protein pseudokinases signal new adventures in cell biology
Patrick A. Eyers et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Oncogenic ERBB3 Mutations in Human Cancers
Bijay S. Jaiswal et al.
CANCER CELL (2013)
Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation
Shyhmin Huang et al.
CANCER RESEARCH (2013)
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
Andrew P. Garner et al.
CANCER RESEARCH (2013)
KSR2 Mutations Are Associated with Obesity, Insulin Resistance, and Impaired Cellular Fuel Oxidation
Laura R. Pearce et al.
CELL (2013)
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Qingsong Liu et al.
CHEMISTRY & BIOLOGY (2013)
TRIB3 Mediates Glucose-Induced Insulin Resistance via a Mechanism That Requires the Hexosamine Biosynthetic Pathway
Wei Zhang et al.
DIABETES (2013)
The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism
James M. Murphy et al.
IMMUNITY (2013)
TRIB2 Acts Downstream of Wnt/TCF in Liver Cancer Cells to Regulate YAP and C/EBPα Function
Jiayi Wang et al.
MOLECULAR CELL (2013)
Structure of the PAN3 Pseudokinase Reveals the Basis for Interactions with the PAN2 Deadenylase and the GW182 Proteins
Mary Christie et al.
MOLECULAR CELL (2013)
New kinase targets for Alzheimer's disease
Monica Hoyos Flight
NATURE REVIEWS DRUG DISCOVERY (2013)
Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases
Angela V. Toms et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
JAK/STAT signaling in hematological malignancies
W. Vainchenker et al.
ONCOGENE (2013)
Structural Insights into RIP3-Mediated Necroptotic Signaling
Tian Xie et al.
CELL REPORTS (2013)
Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials
Jennifer R. Brown
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family
Stephen C. Artim et al.
BIOCHEMICAL JOURNAL (2012)
Identification of TRIB1 R107L gain-of-function mutation in human acute megakaryocytic leukemia
Takashi Yokoyama et al.
BLOOD (2012)
HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation
David B. Vaught et al.
CANCER RESEARCH (2012)
Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase
Liming Sun et al.
CELL (2012)
Discovery of Potent and Selective Covalent Inhibitors of JNK
Tinghu Zhang et al.
CHEMISTRY & BIOLOGY (2012)
Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
John Mascarenhas et al.
CLINICAL CANCER RESEARCH (2012)
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Tjeerd Barf et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F
Rajintha M. Bandaranayake et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
With-No-Lysine Kinase 3 (WNK3) stimulates glioma invasion by regulating cell volume
Brian R. Haas et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2011)
Tribbles in disease: Signaling pathways important for cellular function and neoplastic transformation
Takashi Yokoyama et al.
CANCER SCIENCE (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
KSR1 is a functional protein kinase capable of serine autophosphorylation and direct phosphorylation of MEK1
Jeremy A. Goettel et al.
EXPERIMENTAL CELL RESEARCH (2011)
Cysteine Mapping in Conformationally Distinct Kinase Nucleotide Binding Sites: Application to the Design of Selective Covalent Inhibitors
Emeline Leproult et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Irreversible Nek2 Kinase Inhibitors with Cellular Activity
Jeffrey C. Henise et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK
Damian F. Brennan et al.
NATURE (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling
Daniela Ungureanu et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBPα
K. B. Grandinetti et al.
ONCOGENE (2011)
The minimal kinome of Giardia lamblia illuminates early kinase evolution and unique parasite biology
Gerard Manning et al.
GENOME BIOLOGY (2011)
Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design
Charlotte A. Dodson et al.
BIOCHEMICAL JOURNAL (2010)
A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
Wenjun Zhou et al.
CHEMISTRY & BIOLOGY (2010)
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang et al.
NATURE (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Molecular mechanisms of necroptosis: an ordered cellular explosion
Peter Vandenabeele et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells
F. Zanella et al.
ONCOGENE (2010)
JAK2 V617F Constitutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors
Alexandra Dusa et al.
PLOS ONE (2010)
Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
Wen-I Wu et al.
PLOS ONE (2010)
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Fumin Shi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Evolution of CASK into a Mg2+-Sensitive Kinase
Konark Mukherjee et al.
SCIENCE SIGNALING (2010)
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics
Dhara N. Amin et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2010)
Protein Kinases as Drug Development Targets for Heart Disease Therapy
Naranjan S. Dhalla et al.
PHARMACEUTICALS (2010)
Targeting the cancer kinome through polypharmacology
Zachary A. Knight et al.
NATURE REVIEWS CANCER (2010)
Kinase suppressor of Ras transphosphorylates c-Raf-1
Mohammad Zafrullah et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
The Pseudoactive Site of ILK Is Essential for Its Binding to α-Parvin and Localization to Focal Adhesions
Koichi Fukuda et al.
MOLECULAR CELL (2009)
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
Natalia Jura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Structure of the LKB1-STRAD-MO25 Complex Reveals an Allosteric Mechanism of Kinase Activation
Elton Zeqiraj et al.
SCIENCE (2009)
Structure of the Pseudokinase VRK3 Reveals a Degraded Catalytic Site, a Highly Conserved Kinase Fold, and a Putative Regulatory Binding Site
Eric D. Scheeff et al.
STRUCTURE (2009)
ATP and MO25 alpha Regulate the Conformational State of the STRAD alpha Pseudokinase and Activation of the LKB1 Tumour Suppressor
Elton Zeqiraj et al.
PLOS BIOLOGY (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice
Xu Huang et al.
BIOCHEMICAL JOURNAL (2008)
The ERBB3 receptor in cancer and cancer gene therapy
G. Sithanandam et al.
CANCER GENE THERAPY (2008)
CASK functions as a Mg2+-independent neurexin kinase
Konark Mukherjee et al.
CELL (2008)
WNK2 modulates MEK1 activity through the Rho GTPase pathway
Sonia Moniz et al.
CELLULAR SIGNALLING (2008)
Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F
Xiaohui Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Redox regulation of cAMP-dependent protein kinase signaling - Kinase versus phosphatase inactivation
Kenneth M. Humphries et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Down-regulation of WNK1 protein kinase in neural progenitor cells suppresses cell proliferation and migration
Xutong Sun et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Tribbles homolog 2 inactivates C/EBPα and causes acute myelogenous leukemia
Karen Keeshan et al.
CANCER CELL (2006)
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu et al.
NATURE CHEMICAL BIOLOGY (2006)
TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism
Ling Qi et al.
SCIENCE (2006)
Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides
A Schirmer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Emerging roles of pseudokinases
Jerome Boudeau et al.
TRENDS IN CELL BIOLOGY (2006)
Substrate specificity and activity regulation of protein kinase MELK
M Beullens et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2
A Wissner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Structural bioinformatics-based design of selective, irreversible kinase inhibitors
MS Cohen et al.
SCIENCE (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Introduction to the Kinases in Diabetes Biochemical Society focused meeting: are protein kinases good targets for antidiabetic drugs?
MP Coghlan et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors
CW Lindsley et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Enhanced dephosphorylation of cAMP-dependent protein kinase by oxidation and thiol modification
KM Humphries et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells
RL Kortum et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1
JM Lizcano et al.
EMBO JOURNAL (2004)
The mouse kinome: Discovery and comparative genomics of all mouse protein kinases
S Caenepeel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Analysis of the LKB1-STRAD-MO25 complex
J Boudeau et al.
JOURNAL OF CELL SCIENCE (2004)
Identification of a commonly amplified 4.3 Mb region with overexpression of C8FW, but not MYC in MYC-containing double minutes in myeloid malignancies
CT Storlazzi et al.
HUMAN MOLECULAR GENETICS (2004)
Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer
HR Xing et al.
NATURE MEDICINE (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The role of titin in muscular disorders
JPV Hackman et al.
ANNALS OF MEDICINE (2003)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction
P Saharinen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Imatinib: a selective tyrosine kinase inhibitor
PW Manley et al.
EUROPEAN JOURNAL OF CANCER (2002)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo
A Nguyen et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Protein kinases - the major drug targets of the twenty-first century?
P Cohen
NATURE REVIEWS DRUG DISCOVERY (2002)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
KSR is a scaffold required for activation of the ERK/MAPK module
F Roy et al.
GENES & DEVELOPMENT (2002)
Human hypertension caused by mutations in WNK kinases
FH Wilson et al.
SCIENCE (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
被撤回的出版物: Kinase suppressor of ras signals through Thr269 of c-Raf-1 (Retracted article. See vol. 288, pg. 34053, 2013)
HR Xing et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
A chemical switch for inhibitor-sensitive alleles of any protein kinase
AC Bishop et al.
NATURE (2000)
WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II
BE Xu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Regulation of the Jak2 tyrosine kinase by its pseudokinase domain
P Saharinen et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
A Rossi et al.
NATURE (2000)
分享论文
